<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646851</url>
  </required_header>
  <id_info>
    <org_study_id>PI2017_843_0024</org_study_id>
    <nct_id>NCT03646851</nct_id>
  </id_info>
  <brief_title>Aspergillus and Chronic Obstructive Pulmonary Disease Evolution</brief_title>
  <acronym>AspergBPCO</acronym>
  <official_title>Impact of Aspergillus on Chronic Obstructive Pulmonary Disease Evolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter cohort study which includes all consecutive COPD patients
      who come for a visit in one the participating pneumologist. They will have to do a sputum and
      to complete some questionnaries. Questionnaries will be redone by phone after 1 and 3 months
      and during the visit after 6 months. We will correlate aspergillus presence in sputum with
      quality of life (QoL), and COPD symptoms evaluated by questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aspergillosis disease is a growing problem. These diseases are not yet uncommon in chronic
      obstructive pulmonary disease patients. (COPD).

      Aspergillosis disease are very difficult to be diagnosed or treated. Isolation of aspergillus
      in sputum of patients is not always responsible of a real disease. Need of treatment is
      discussed. That is why, we will conduct a prospective cohort study to evaluate aspergillus
      rate in respiratory samples of COPD patients (GOLD stage III or IV)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence of aspergillus in sputum or respiratory samples</measure>
    <time_frame>one year before inclusion</time_frame>
    <description>sputum examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea with MMRC score</measure>
    <time_frame>day of inclusion</time_frame>
    <description>Pulmonary function testing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD patients GOLD stage III and IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Questionnaries</intervention_name>
    <description>patients will have to do a sputum and to complete some questionnaries</description>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients GOLD stage III and IV

        Exclusion Criteria:

          -  Cystic fibrosis

          -  Pulmonary fibrosis

          -  hematological malignancy

          -  known aspergilloma

          -  allergic bronchopulmonary aspergillosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CH Abbeville</name>
      <address>
        <city>Abbeville</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Quentin</name>
      <address>
        <city>Saint-Quentin</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

